Trials
Search / Trial NCT05639192

Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease

Launched by APOGENIX GMBH · Dec 3, 2022

Trial Information

Current as of February 05, 2025

Terminated

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patient must be willing and able to give informed consent to participate in the trial and to adhere to the procedures stated in the protocol
  • ≥18 years of age
  • Patient is admitted to a hospital (max. 72 hours prior to randomization) due to COVID-19 and has a positive SARS-CoV-2 PCR test
  • Clinical symptoms indicative of moderate or severe illness (corresponding to score 5 or 6 on the WHO 10-point clinical progression scale) with COVID 19 prior to trial treatment
  • Patient agrees to not participate in another clinical trial from screening until day 56
  • Exclusion Criteria:
  • Patient is moribund or has an estimated life expectancy \<1 month (e.g., terminal cancer, etc.)
  • Patient is anticipated to be discharged from hospital within 48 hours
  • Patient requires anti-inflammatory medicines beyond SoC (SoC are drugs that are approved for treatment of COVID-19 as well as medicines that have been recommended in treatment guidelines of national health authorities and/or professional organization)
  • Patient requires invasive mechanical ventilation
  • Patient is known to have active tuberculosis
  • Patient is known to have hereditary fructose intolerance.
  • Patient is known to have co-infection with Influenza viruses or other viral respiratory infections (respiratory syncytial virus \[RSV\], parainfluenza viruses, respiratory adenoviruses).

Trial Officials

Eike C. Buss, MD

Study Chair

Apogenix AG

About Apogenix Gmbh

Apogenix GmbH is a biopharmaceutical company focused on developing innovative therapeutic solutions for cancer and other serious diseases. With a strong emphasis on harnessing the power of the immune system, Apogenix is advancing its proprietary platform of drug candidates designed to target and modulate immune responses. The company is dedicated to conducting rigorous clinical trials to evaluate the safety and efficacy of its therapies, aiming to improve patient outcomes and quality of life. Committed to scientific excellence and collaboration, Apogenix strives to bring transformative treatments from the lab to the clinic.

Locations

Heidelberg, , Germany

Barcelona, , Spain

Valladolid, , Spain

Limoges, , France

Paris, , France

Benoni, , South Africa

Johannesburg, , South Africa

Mysore, Karnataka, India

Madrid, , Spain

Milan, , Italy

Salamanca, , Spain

Milano, , Italy

Wien, , Austria

Amiens, , France

Kutaisi, , Georgia

Tbilisi, , Georgia

Tbilisi, , Georgia

Tbilisi, , Georgia

Tbilisi, , Georgia

Köln, , Germany

Visakhapatnam, Andrha Pradesh, India

Bangalore, Karnataka, India

Pune, Maharashta, India

Aurangabad, Maharashtra, India

Pune, Maharashtra, India

Lucknow, Uttar Pradesh, India

Bangalore, , India

Nehru Nagar, , India

Sūrat, , India

Napoli, , Italy

Napoli, , Italy

Bolesławiec, , Poland

Koszalin, , Poland

Wrocław, , Poland

Three Rivers, , South Africa

Alicante, , Spain

Vigo, , Spain

Brive La Gaillarde, , France

Ulhasnagar, Maharashtra, India

Pretoria, Gauteng, South Africa

Durban, , South Africa

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials